Join our daily newsletter At The Bell to receive exclusive market insights
- Resonance Health (RHT) is contracted to provide services for two new clinical trials addressing iron-overload disorders
- The company has signed contracts with two new pharmaceutical customers to provide FerriScan, Cardiac-T2, and related analysis services for the clinical trials
- The new customers bring Resonance’s current number of contracted studies to 12
- Each trial is expected to have a duration of 28 months with a combined value of up to $1.5 million payable to RHT over the 28-month duration of each trial
- Resonance Health is up 7.69 per cent and trading at 7 cents at 1:57 pm AEDT
Resonance Health (RHT) has been contracted to provide services for two new clinical trials addressing iron-overload disorders.
The company has signed contracts with two new pharmaceutical customers to provide FerriScan, Cardiac-T2, and related analysis services for the clinical trials, increasing the number of studies currently contracted and being serviced by Resonance Health to 12.
Ferriscan provides an accurate measurement of liver iron concentration through a non-invasive MRI-based technology, while Cardiac-T2 is an MRI method for assessing heart iron loading.
Each trial is expected to have a duration of 28 months.
RHT said iron overload disorders affect millions of people globally, most notably in diseases such as thalassaemia, sickle-cell disease and hereditary hemochromatosis.
The first clinical trial is valued at up to €860,000 (A$1.5 million), payable over the duration of the study.
The second trial contract is with a US company, with the total service fees comprising both fixed and variable fees.
Managing Director of Resonance Health Mitchell Wells said it was pleasing to contract with these new commercial customers so soon after launching its Resonance Clinical initiative.
“Once again, Resonance Health will be engaging in the important work of assisting pharmaceutical companies develop drugs and treatments for patients with liver diseases,” Mr Wells said.
“We look forward to working with our new customers, and we wish them the best with their pursuit to improve the lives of people with iron-overload disorders.”
Resonance Health is up 7.69 per cent and trading at 7 cents at 1:57 pm AEDT.
